Stakeholders:Natalie Kuzla, Program Manager for PRECINCTJim Dattilo, Senior Clinical Data Manger for PRECINCTQi Long, PINicola (Nikki) MasonData Types Collected:Data collected in PRECINCT:Clinical trial data/observationsGenomic DNA sequence (including cfDNA) – WES, WGSRNA sequenceqRT-PCR (e.g. for cytokines)Flow cytometry (surface antigens for tumor and immune phenotyping, intracellular markers and cytokines)Immunohistochemistry (tumor, LN biopsies)Cytokine/chemokine levels (ELISA, EliSpot)Imaging – MRI, PETProliferation assays (CFSE)Cytotoxicity assays (51Cr release)ADCC assaysVirus Titers (HSV)
<ul>
  <li>
    <h2 id="PRECINCTDataInventory-https://dctd.cancer.gov/NewsEvents/20190327_canine_immunotherapy.htm">
      <a href="https://dctd.cancer.gov/NewsEvents/20190327_canine_immunotherapy.htm" rel="nofollow">
        https://dctd.cancer.gov/NewsEvents/20190327_canine_immunotherapy.htm
      </a>
    </h2>
  </li>
  <li>
    <h1 id="PRECINCTDataInventory-CoordinatingCenterforCanineImmunotherapyTrialsandCorrelativeStudiesMason,NicolaJ.Propert,KathleenJoyUniversityofPennsylvania,Philadelphia,PA,UnitedStates">
      <a href="http://grantome.com/grant/NIH/U24-CA224122-01" rel="nofollow">
        Coordinating Center for Canine Immunotherapy Trials and Correlative Studies
      </a>
      <a title="Link to Mason&#39;s Pubmed publication list..." href="http://www.ncbi.nlm.nih.gov/pubmed?term=Mason+NJ%5BAuthor%5D" rel="nofollow">
        Mason, Nicola J.
      </a>
      <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Propert+KJ%5BAuthor%5D" title="Link to Propert&#39;s Pubmed publication list..." rel="nofollow">
        Propert, Kathleen Joy
      </a>
      <a title="Link to University of Pennsylvania website..." href="http://www.upenn.edu/" rel="nofollow">
        University of Pennsylvania, Philadelphia, PA, United States
      </a>
    </h1>
  </li>
  <li>
    <h2 id="PRECINCTDataInventory-https://deainfo.nci.nih.gov/advisory/bsa/1016/1_CanineTrials.pdf(DescriptionofUM1/U24grantsandrelationships)">
      <a href="https://deainfo.nci.nih.gov/advisory/bsa/1016/1_CanineTrials.pdf" rel="nofollow">
        https://deainfo.nci.nih.gov/advisory/bsa/1016/1_CanineTrials.pdf
      </a>
       (Description of UM1/U24 grants and relationships)
    </h2>
  </li>
</ul>
<h2 id="PRECINCTDataInventory-U24Holder-DataCoordinatingCenterforU01Holders">
  <a href="https://wiki.nci.nih.gov/pages/viewpage.action?pageId=388041925" rel="nofollow">
    U24 Holder - Data Coordinating Center for U01 Holders
  </a>
</h2>
in cooperation with NCI COP and NCI program staff:•Help develop and implement clinical studies•Assist in standardization of clinical and laboratory protocols•Manage clinical and correlative data and provide statistical support•Facilitate sharing of agent, specimens and data
<table>
  <colgroup>
    <col/>
    <col/>
    <col/>
  </colgroup>
  <tbody>
    <tr>
      <td>
        Institution
      </td>
      <td>
        Project Leader(s)
      </td>
      <td>
        Canine Cancer(s)
      </td>
    </tr>
    <tr>
      <td colspan="1">
        U Penn
      </td>
      <td colspan="1">
        Nicola Mason/Kathleen Propert
      </td>
      <td colspan="1">
        U24 coordinating center
      </td>
    </tr>
  </tbody>
</table>
<ol>
  <li>
    Collecting data in the following areas:
  </li>
  <li>
    Clinical trial data/observations
  </li>
  <li>
    Genomic DNA sequence (including cfDNA) – WES, WGS
  </li>
  <li>
    RNA sequence
  </li>
  <li>
    qRT-PCR (e.g. for cytokines)
  </li>
  <li>
    Flow cytometry (surface antigens for tumor and immune phenotyping, intracellular markers and cytokines)
  </li>
  <li>
    Immunohistochemistry (tumor, LN biopsies)
  </li>
  <li>
    Cytokine/chemokine levels (ELISA, EliSpot)
  </li>
  <li>
    Imaging – MRI, PET
  </li>
  <li>
    Proliferation assays (CFSE)
  </li>
  <li>
    Cytotoxicity assays (51Cr release)
  </li>
  <li>
    ADCC assays
  </li>
  <li>
    Virus Titers (HSV)
  </li>
</ol>
<h2 id="PRECINCTDataInventory-UM1Holders-ClinicalData">
  UM1 Holders - Clinical Data
</h2>
•Conduct canine clinical trials using immunotherapeutic agents and novel combinations•Correlative studies to characterize and understand the cellular and molecular mechanisms that determine response (or non-response)
<table>
  <colgroup>
    <col/>
    <col/>
    <col/>
  </colgroup>
  <tbody>
    <tr>
      <td>
        Institution
      </td>
      <td>
        Project Leader(s)
      </td>
      <td>
        Canine Cancer(s)
      </td>
    </tr>
    <tr>
      <td>
        Colorado State U
      </td>
      <td>
        Steven Dow/Cheryl London
      </td>
      <td>
        Osteosarcoma, novel immunotherapy combinations
      </td>
    </tr>
    <tr>
      <td>
        U of Alabama at Birmingham
      </td>
      <td>
        MR Chambers
      </td>
      <td>
        Glioma, immuno-neurotherapeutics
      </td>
    </tr>
    <tr>
      <td>
        U of Minnesota
      </td>
      <td>
        Grace Elizabeth Pluhar
      </td>
      <td>
        Glioma, immunotherapy combinations
      </td>
    </tr>
    <tr>
      <td>
        UC Davis
      </td>
      <td>
        Robert Canter/Robert Rebhun
      </td>
      <td>
        Melanoma and osteosarcoma, NK immunotherapy
      </td>
    </tr>
    <tr>
      <td>
        Tufts U
      </td>
      <td>
        Cheryl London/Kristy Richards
      </td>
      <td>
        B-cell lymphoma, immunotherapy combinations
      </td>
    </tr>
  </tbody>
</table>
<a href="/display/ICDC/PRECINCT+Data+Inventory?preview=%2F388041925%2F388041930%2FPRECINCT01_DataDictionary_2018-11-15.xlsx" rel="nofollow">
  PRECINCT01_DataDictionar…
</a>
<a href="/display/ICDC/PRECINCT+Data+Inventory?preview=%2F388041925%2F388041927%2FPRECINCT+CRFs+V1.0.20180918.pdf" rel="nofollow">
  PRECINCT CRFs V1.0.20180…
</a>
<a href="/display/ICDC/PRECINCT+Data+Inventory?preview=%2F388041925%2F388041928%2FPRECINCT01+2018-11-15.pdf" rel="nofollow">
  PRECINCT01 2018-11-15.pdf
</a>